Navigation Links
Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
Date:3/31/2009

TEMPE, Ariz., March 31 /PRNewswire/ -- Intrinsic Bioprobes, Inc. today announced the start of a contract with the National Cancer Institute to develop effective technologies for accurate measurement of cancer-related proteins and peptides that improve diagnostic capabilities by effectively discerning diseased from non-diseased states. The total cost of the two-and-a-half-year contract is $1,276,360, out of which $1,130,272 is Federal money provided by the NCI, and $146,088 is the contractor's share provided by Intrinsic Bioprobes, Inc. This contract is in support of NCI's Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research (http://proteomics.cancer.gov).

"The purpose of this contract is to stimulate the development of multiplex mass spectrometric immunoassay for the detection of low abundance cancer-related proteins/peptides from bodily fluids," says Dobrin Nedelkov, Ph.D., the Scientific Director of Intrinsic Bioprobes. "The application of proteomics tools in the clinical setting lags far behind their use in basic science and drug discovery. The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation. The mass spectrometric aspect of the assays also enables single-step detection of protein isoforms and their individual quantification, which is an important protein diversity aspect regularly overlooked in contemporary proteomics approaches," adds Nedelkov.

Intrinsic Bioprobes, Inc. is a privately held Biotechnology Company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis
'/>"/>

SOURCE Intrinsic Bioprobes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
3. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
6. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
9. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
10. Sangui Partnership Enters a New Phase:
11. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...charge their cell phones and other personal electr...y made by UC San Diego engineers could lead to car...ust this. , In recent research, published in A...essor in the UCSD Department of Mechanical and Aer...rk Hoefer, have found that artificially introduced...
(Date:11/19/2009)...swire/ -- Dr. Mate Hidvegi, inventor of Avemar fer...ease issued on November 17 by Biropharma Kft, disc...d self-serving statements about its U.S. competito...from his office in Budapest, Hungary: ,, "The ...apply to AveULTRA, www.aveultra.com , is mislea...
(Date:11/19/2009)...wire-FirstCall/ -- Spherix Incorporated (Nasdaq: ... therapy, and a provider of technical and regulato...hnology and pharmaceutical companies, today announ...reholders. ,, At the meeting, shareholders of S...ollowing members to the Board of Directors: ,, ...
(Date:11/19/2009)... - Aegera Therapeutics Inc. announced today the do... study of AEG35156, a targeted antisense therapeut...indications. ,, The study, entitled "An Open-La...itor of Apoptosis (XIAP) Antisense AEG35156 Given ...bicin in AML Following Failure of a Single Standar...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
... of potential vaccine for low-resource countries ,...e biotech company Lentigen Corporation and the non...oday a partnership to accelerate research on a pan...t $3 million over 27 months and work with Lentigen...article (VLP) prototype pandemic influenza vaccine...
...E Alternext US: NBS), which is pioneering the pre-...e of adult stem cells for future medical need,toda...in its current business,plan with the opening of t...adult stem cells by the general public for future ... Yaffe, M.D., Yaffe, Ruden and Associates (founder...
...ar-old,prostate cancer patient from Montpellier ha...using RapidArc(TM) technology from Varian Medical ...of intensity modulated radiotherapy,(IMRT). Each o...Lamarque in,the city took just 75 seconds, several...r. Pascal Fenoglietto, the hospital,s chief medica...
Other Biology Technology:Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 2Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 2NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 4Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 3
(Date:11/20/2009)...t published in the November 2009 issue of the jour...ists show how a family of genes (1-aminocyclopropa...nsible for production of ethylene. This gas affect...rmation lays the foundation for future genetic man..., able to survive and thrive in difficult terrain,...
(Date:11/20/2009)...e measurements of plasma lipoprotein concentration...scopy (NMR), researchers led by Daniel Chasman at ...chool in Boston, MA, the Framingham Heart Study in...holm, Sweden and Oxford, England performed genetic...g 17,296 women of European ancestry from the Women...
(Date:11/20/2009)...ited to contribute their abstracts to the World Co...e largest global meeting devoted to all aspects of...ent care. The Congress will be held in Florence, I...racts can be submitted online at http://www.iofwc...ruary 4, 2010. , IOF and ESCEO are pleased to an...
Breaking Biology News(10 mins):It's a gas: New discovery may lead to heartier, high-yielding plants 2Genetic analysis helps dissect molecular basis of cardiovascular disease 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Anthem Life offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with the Loss of a Loved One 56223 1Anthem Life offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with the Loss of a Loved One 56223 2Visit AARPs Kernels for Healthcare Reform and Cast Your Vote 56220 1Visit AARPs Kernels for Healthcare Reform and Cast Your Vote 56220 2Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 13852 1
... the new study, the presence of caspase-12, which ...ty in humans, increases the body,s "vulnerability ...eficiency confers strong resistance to sepsis. Thi...ts could be a potentially useful in the treatment ...ers. , The study was published in the April 20 ed...
...at Harvard Medical School (HMS) report in the Apri...rons that encode the values that subjects assign t...ight facilitate the process of decision-making tha...ods. , "We have long known that different neurons ...attributes, such as quantity, color, and taste. Bu...
...from Rensselaer Polytechnic Institute and the Univ...ly of molecules that successfully counteracts and ...periments. The novel approach used to neutralize a...therapeutics for a variety of pathogens and toxins...ecreted by the anthrax bacterium, is made of prote...
Other Biology News:Lack of a key enzyme dramatically increases resistance to sepsis 2Lack of a key enzyme dramatically increases resistance to sepsis 3Attention shoppers: Researchers find neurons that encode the value of different goods 2Attention shoppers: Researchers find neurons that encode the value of different goods 3Anthrax inhibitor counteracts toxin, may lead to new therapeutics 2Anthrax inhibitor counteracts toxin, may lead to new therapeutics 3
Peptide Antibody from Proteintech Group, Inc.
Bovine Albumin from Bovine Serum, Texas Red conjugated/tagged from Molecular Probes (Invitrogen)
Essential Techniques: Antibody Production from Promega
Dynabeads Epithelial Enrich from Dynal Biotech
Biology Products: